

## Special Issue

# Human Leukocyte Antigen (HLA) and Vaccines

### Message from the Guest Editors

The success of vaccines in preventing illness depends on our ability to make antibodies against the pathogen components contained in the vaccines; if antibodies cannot be made, the vaccine will not be effective. In this case, vaccine antigens persist with the possibility of causing cell damage either directly or via molecular mimicry and autoimmunity. Now, the mounting of antibodies against specific antigens critically depends on the individual's Human Leukocyte Antigen (HLA) Class 2 genetic makeup, which consists of more than six alleles (two for each of the DRB1, DQB1, and DPB1 genes, plus the occasional DRB3, DRB4, and DRB5 allele). This Special Issue will focus on this matter, which is of major medical and public health importance but hardly covered elsewhere.

---

### Guest Editors

Prof. Dr. Apostolos P. Georgopoulos

Dr. Effie-Photini Tsilibary

Dr. Lisa M. James

Dr. Spyros Charonis

---

### Deadline for manuscript submissions

closed (31 January 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/44434](https://mdpi.com/si/44434)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).